FDA and AAM Reach Tentative Agreement on GDUFA IV, Waiving U.S.-Made Generic Drug Fees
GDUFA IV Tentative Agreement and a Shift Towards U.S.-Based Regulation
The FDA and the Alliance for Generic Medicines (AAM), along with other pharmaceutical organizations, have reached a tentative agreement on the Generic Drug User Fee Amendments IV (GDUFA IV), which will apply from 2028 to 2032. With the current GDUFA III framework expiring on September 30, 2027, both parties proactively concluded negotiations to ensure the continuity of regulatory reviews and financial stability. This agreement goes beyond simply setting fee levels; it directly incorporates the broader policy goal of strengthening the U.S. domestic pharmaceutical supply chain into the regulatory system.
Introduction of 'America First' Fee Waivers and Supply Chain Restructuring
The most significant aspect of this tentative agreement is the 'America First' application fee waiver, offered to companies that produce active pharmaceutical ingredients (APIs) and finished drug products (FDPs) within the United States. By agreeing to waive fees for one application for generic drugs that undergo manufacturing in U.S. facilities, the agreement significantly incentivizes companies to onshore their operations. This reflects the FDA's strong commitment to resolving drug shortages caused by high dependence on overseas sources, particularly from India and China, and to restoring the domestic manufacturing ecosystem.
Increased Fees for Overseas Facility Inspections and Cost Burden for Global Generic Companies
While providing incentives for domestic manufacturers, the regulatory hurdles for overseas production facilities will be further increased. The FDA and the industry have agreed to significantly increase the differential for foreign facility inspection fees, from the current $15,000 to $25,000. This aims to secure resources for maintaining rigorous quality inspections of overseas manufacturing facilities and will directly impact the cost structure of global generic pharmaceutical companies with high proportions of overseas production, such as Teva and Viatris.
Technical Improvements to Enhance Predictability and Efficiency of Reviews
In addition to financial changes, the agreement includes various technical measures to improve the efficiency of drug reviews. Specifically, it aims to establish a database of 500 or more maximum daily dose (MDD) data by the end of fiscal year 2028 to support the safety assessment of excipients. Furthermore, by adjusting the application date for program fees to May 1, it prevents double-billing, providing a safeguard that minimizes administrative confusion and unnecessary financial burdens for small and medium-sized generic companies.
Upcoming Legislative Process and Impact on the Generic Investment Market
The tentative agreement reached will be formalized into a final commitment letter and then undergo the legislative process in the U.S. Congress for final confirmation. The generic drug market operates with an annual fee revenue of over $600 million, and this regulatory reform could significantly alter the profitability of companies in the long term. Investors should comprehensively analyze the margin improvement effects for companies with domestic production facilities and the increased inspection costs for companies with high proportions of overseas outsourcing.
This GDUFA IV tentative agreement restructures the FDA's generic drug fee revenue, which was $638.96 million in FY 2025, providing preferential advantages to pharmaceutical companies with domestic manufacturing infrastructure in the U.S. In the short term, the ANDA application fee, which is $358,247 per application in FY 2026, will be waived for U.S.-made APIs and FDPs, leading to visible cost savings for companies with local production bases such as Teva and Viatris. In the medium to long term, however, the increase in overseas inspection fees from $15,000 to $25,000 will increase the pressure on companies that rely on overseas outsourcing to reduce their unit costs. From a development perspective, the establishment of a database of 500 or more maximum daily doses (MDD) by 2028 is expected to reduce the uncertainty of complex generic drug approvals. This reform, which is awaiting congressional approval, will accelerate the onshoring of global supply chains and reshape the medium- to long-term margin structure of generic pharmaceutical companies.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iv-fiscal-years-2028-2032